Multidimensional effects of metformin in patients with type 2 diabetes

In modern algorithms for the treatment of type 2 diabetes, metformin is positioned as a first-line drug, which, when the disease progresses, is universally combined with other groups of hypoglycemic drugs, including insulin. Review of literature demonstrates the multifaceted effects of metformin wit...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lyudmila A. Ruyatkina, Dmitriy S. Ruyatkin
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2017
Materias:	diabetes mellitus metformin glucophage long Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/42c44c268da24bf5b6a47d750c9d373d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:42c44c268da24bf5b6a47d750c9d373d
record_format	dspace
spelling	oai:doaj.org-article:42c44c268da24bf5b6a47d750c9d373d2021-11-14T09:00:21ZMultidimensional effects of metformin in patients with type 2 diabetes2072-03512072-037810.14341/DM2003458-64https://doaj.org/article/42c44c268da24bf5b6a47d750c9d373d2017-08-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/8676https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378In modern algorithms for the treatment of type 2 diabetes, metformin is positioned as a first-line drug, which, when the disease progresses, is universally combined with other groups of hypoglycemic drugs, including insulin. Review of literature demonstrates the multifaceted effects of metformin with its efficacy and extensive safety range, allowing the drug to be used not only for glycemic control but also for the management of cardiovascular risk factors. Here we present a retrospective study of whether cardiovascular safety of hypoglycemic drugs should be assessed, on the basis of which the idea of a “vulnerable patient” in the presence of diabetes can be formulated, and the necessity of joint management of such patients by an endocrinologist and cardiologist can be postulated. The mechanisms of macrovascular protection by the drug demonstrated in the UKPDS with the phenomenon of “metabolic memory” are analysed along with a discussion regarding their lipid-lowering and antisclerotic effects using modern analytical reviews. The features of the action of long form of the drug (Glucophage Long) are considered. The pleiotropic possibilities of metformin, the expansion of the present indications and the prospects of application as well as new hypotheses about its mechanism of action are discussed. The possible effects of the drug on the components of the “gastrointestinal tract–brain–liver” axis are discussed, and the effects of metformin on homeostasis due to the effect on the microbiota are presented.Lyudmila A. RuyatkinaDmitriy S. RuyatkinEndocrinology Research Centrearticlediabetes mellitusmetforminglucophage longNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 20, Iss 3, Pp 210-219 (2017)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	diabetes mellitus metformin glucophage long Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	diabetes mellitus metformin glucophage long Nutritional diseases. Deficiency diseases RC620-627 Lyudmila A. Ruyatkina Dmitriy S. Ruyatkin Multidimensional effects of metformin in patients with type 2 diabetes
description	In modern algorithms for the treatment of type 2 diabetes, metformin is positioned as a first-line drug, which, when the disease progresses, is universally combined with other groups of hypoglycemic drugs, including insulin. Review of literature demonstrates the multifaceted effects of metformin with its efficacy and extensive safety range, allowing the drug to be used not only for glycemic control but also for the management of cardiovascular risk factors. Here we present a retrospective study of whether cardiovascular safety of hypoglycemic drugs should be assessed, on the basis of which the idea of a “vulnerable patient” in the presence of diabetes can be formulated, and the necessity of joint management of such patients by an endocrinologist and cardiologist can be postulated. The mechanisms of macrovascular protection by the drug demonstrated in the UKPDS with the phenomenon of “metabolic memory” are analysed along with a discussion regarding their lipid-lowering and antisclerotic effects using modern analytical reviews. The features of the action of long form of the drug (Glucophage Long) are considered. The pleiotropic possibilities of metformin, the expansion of the present indications and the prospects of application as well as new hypotheses about its mechanism of action are discussed. The possible effects of the drug on the components of the “gastrointestinal tract–brain–liver” axis are discussed, and the effects of metformin on homeostasis due to the effect on the microbiota are presented.
format	article
author	Lyudmila A. Ruyatkina Dmitriy S. Ruyatkin
author_facet	Lyudmila A. Ruyatkina Dmitriy S. Ruyatkin
author_sort	Lyudmila A. Ruyatkina
title	Multidimensional effects of metformin in patients with type 2 diabetes
title_short	Multidimensional effects of metformin in patients with type 2 diabetes
title_full	Multidimensional effects of metformin in patients with type 2 diabetes
title_fullStr	Multidimensional effects of metformin in patients with type 2 diabetes
title_full_unstemmed	Multidimensional effects of metformin in patients with type 2 diabetes
title_sort	multidimensional effects of metformin in patients with type 2 diabetes
publisher	Endocrinology Research Centre
publishDate	2017
url	https://doaj.org/article/42c44c268da24bf5b6a47d750c9d373d
work_keys_str_mv	AT lyudmilaaruyatkina multidimensionaleffectsofmetformininpatientswithtype2diabetes AT dmitriysruyatkin multidimensionaleffectsofmetformininpatientswithtype2diabetes
_version_	1718429521132126208

Multidimensional effects of metformin in patients with type 2 diabetes

Ejemplares similares